Istituto Oncologico Veneto

The strongest research focus at Istituto Oncologico Veneto is in neoplasms and hemic and lymphatic diseases, with studies centered on blood cancers and solid tumors. Trials are exploring better treatment options for acute myeloid leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and chronic myeloid leukemia, alongside cancers such as prostate cancer, bladder cancer, and biliary tract cancers. The main aim is to test new therapies and improve how effectively current treatments control disease.

• Blood cancer research includes acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia, with a strong emphasis on improving remission and survival outcomes.
• Lymphoma studies address follicular lymphoma, marginal zone lymphoma, and diffuse large B-cell lymphoma, often comparing newer immunotherapy-based approaches with established care.
• Solid tumor trials include prostate cancer, bladder cancer, ovarian cancer, Merkel cell carcinoma, and biliary tract cancers, focusing on treatment effectiveness and disease control.

This broad oncology portfolio reflects a commitment to evaluating innovative cancer treatments, refining existing regimens, and improving outcomes for patients with both common and rare malignancies.

A major research theme at the site is the use of targeted therapy and precision medicine to match treatment more closely to each disease subtype. Studies are examining therapies for genetically defined or biomarker-driven cancers, including FLT3-positive acute myeloid leukemia, NPM1-mutated AML, KMT2Ar AML, and metastatic castration-resistant prostate cancer. These trials are designed to improve response rates and delay disease progression.

• Research in acute myeloid leukemia includes biomarker-guided approaches aimed at improving remission and long-term control.
• Prostate cancer studies are testing whether new hormone-based and targeted strategies can better slow advanced disease.
• Molecularly informed trials in lymphoma are evaluating whether treatment can be better tailored to patient and disease features.

The work in this area highlights a shift toward more individualized cancer care, with the goal of improving effectiveness while keeping treatment appropriate for specific disease profiles.

The site is also active in immunotherapy research, often combining immune-based treatments with other anticancer approaches. Trials are studying follicular lymphoma, marginal zone lymphoma, Merkel cell carcinoma, and advanced biliary tract cancers, with the purpose of strengthening treatment response and improving disease control. These studies help assess whether combination strategies can outperform standard care.

• Lymphoma trials are testing immune-based combinations to improve progression-free survival and reduce relapse risk.
• In solid tumors, immunotherapy is being explored as a way to enhance tumor response and support surgery or chemotherapy.
• Several studies focus on whether adding immune treatment can improve outcomes compared with established regimens alone.

This area of research shows a clear interest in building more effective treatment combinations for cancers that remain difficult to manage with standard therapy.

Beyond cancer treatment, Istituto Oncologico Veneto contributes to studies in hematology and other disease areas, including haemophilia, respiratory tract diseases, and cardiovascular diseases. These trials are focused on improving supportive care, reducing complications, and evaluating whether new approaches can better protect patients during treatment or acute illness.

• Hematology research includes studies in haemophilia A and haemophilia B with inhibitors, aimed at reducing bleeding episodes.
• Supportive care trials in chronic lymphocytic leukemia are examining infection prevention during cancer treatment.
• Respiratory research includes acute respiratory distress syndrome, with a focus on improving recovery and clinical outcomes.

These studies broaden the site’s research profile by addressing complications and related conditions that affect patient safety and quality of care.